Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7779086 | 0.84 | SLC18A3 (0.56) | SLC18A3SIGMAR1DRD2DRD3SLC6A4 | |
| SCHEMBL7781788 | 0.79 | SLC18A3 (0.50) | SLC18A3SIGMAR1DRD2DRD3SLC6A4 | |
| SCHEMBL8989690 | 0.77 | DRD2 (0.67) | SLC18A3SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL8989703 | 0.77 | SLC18A3 (0.47) | SLC18A3SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL8179864 | 0.76 | SIGMAR1 (0.56) | SLC18A3SIGMAR1DRD2DRD3SLC6A4 | |
| SCHEMBL8989705 | 0.75 | SLC18A3 (0.43) | SLC18A3SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL7779070 | 0.75 | SLC18A3 (0.46) | SLC18A3SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL9076786 | 0.74 | HTR2A (0.62) | SIGMAR1DRD2DRD3SLC6A4SLC6A3 | |
| SCHEMBL8989762 | 0.74 | SLC18A3 (0.45) | SLC18A3SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL8989700 | 0.74 | GRIN2B (0.45) | SLC18A3SIGMAR1DRD2DRD3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1133293-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000030639-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0646110-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS | BASF AG (DE) | 1996-10-23 | — | — | EP | disclosed |
| US-5521209-A | N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
| EP-0646110-A1 | N-SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| WO-1994000431-A1 | N-SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |